scholarly journals Dys-regulation of Lnc-SNHG1 and miR-216b-5p Correlate With Chemo-resistance and Indicate Poor Prognosis of Serous Epithelial Ovarian Cancer

2020 ◽  
Author(s):  
Mei Li Pei ◽  
Zong Xia Zhao ◽  
Ting Shuang
Keyword(s):  
Ovarian Cancer ◽  
Cox Regression ◽  
Histological Grade ◽  
Disease Free Survival ◽  
Figo Stage ◽  
Tumor Stage ◽  
Nodal Status ◽  
Cancer Tissue ◽  
Chi Square ◽  
Cox Regression Analysis

Abstract Background: Ovarian cancer is the most lethal of gynecological cancers and the 5-year survival rate is still low and chemo-resistance is the main obstacle for the treatment of ovarian cancer. Methods and Results: In this study, the human ovarian cancer tissue microarray was applied, 63 cases of chemo-sensitive serous EOC tissues and 32 cases of chemo-resistant serous EOC tissues were selected. By applying RNA fluorescence in situ hybridization (FISH), we found expression of Lnc-SNHG1 was up-regulated while miR-216b-5p showed low expression in chemo-resistant EOC patients compared with the chemo-sensitive group, both were mainly localized in the cytoplasm of the tissue cells. Chi-square test showed high lnc-SNHG1 level was significantly correlated with tumor stage, histological grade, nodal status, metastasis and chemo-resistance except tumor size. While there was no significant association between miR-216b-5p expression and parameters including tumor stage, histological grade, nodal status, metastasis, except chemo-resistance (P=0.0001). Spearman’s correlation analysis revealed significantly negative correlations between lnc-SNHG1 and miR-216b-5p (r = -0.424, P = 0.0001). Multivariate Cox regression analysis showed the expression of miR-216b-5p (P = 0.012, RR 2.137, 95 % CI 1.109–5.339) and FIGO stage (P = 0.001, RR 3.537, 95 % CI 1.72–7.276) was independent prognostic factors for the overall survival (OS) of serous EOC patients .While the FIGO stage (P = 0.003, RR2.237, 95 % CI 1.323–3.783) was the independent prognostic factor for the disease free survival (DFS) for the serous EOC patients. Kaplan- Meier curves revealed significant association of increased expression of lnc-SNHG1 with less OS and shorter DFS, while patients with low level of miR-216b-5p indicated less OS and DFS. Conclusions: In a word, we claimed over-expression of lnc-SNHG1 and decreased expression of miR-216b-5p were correlated with chemo-resistance of serous EOC patients and indicated less OS and shorter DFS of the patients.

A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients

2009 ◽  
Vol 27 (18_suppl) ◽  
pp. LBA5510-LBA5510 ◽  
Author(s):  
J. Herrstedt ◽  
J. Huober ◽  
F. Priou ◽  
H. Müller ◽  
M. Baekelandt ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Cox Regression ◽  
Residual Tumor ◽  
Figo Stage ◽  
Stage I ◽  
Phase Iii ◽  
Cox Regression Analysis ◽  
Phase Iii Study ◽  
First Diagnosis

LBA5510 Background: One option to increase the efficacy of TC in pts with first diagnosis of ovarian cancer is to add a not cross-resistant drug. Methods: We conducted a randomized, prospective, stratified, phase III study comparing therapy with TC to TC plus gemcitabine. From 7/02 to 4/04, pts with a histological verified first diagnosis of epithelial OC, FIGO IC-IV were randomized to either TC (paclitaxel [T] 175 mg/m2 3h iv d1 + carboplatin [C] AUC 5 iv d1) or TCG (TC + gemcitabine [G] 800 mg/m2 iv d1+8) for at least 6 cycles every 21 days starting within 6 weeks post-operatively. The randomization was balanced within three strata: 1) FIGO I-IIA, 2) FIGO IIB-IIIC with residual tumor ≤ 10mm, 3) FIGO IIB-IIIC with residual tumor > 10 mm or FIGO IV. Primary endpoint is overall survival. Results: We enrolled 1,742 pts and administered 5,268 cycles TC and 5,129 cycles TCG. All baseline characteristics of the patients in both arms were well balanced. Most pts received 6+ cycles (87.2% TC, 86.2% TCG). Previous interim analyses has shown that TCG was tolerable but induced more hematological toxicity and final analysis has shown that addition of gemcitabine did not improve overall survival in patients with FIGO stage IIB-IV disease. Approximately 11% of the patients (n = 175) had FIGO stage I-IIA disease (stratum I). Most patients received 6+ cycles (93.3% TC, 86.9% TCG). With a median follow-up of 53.8 (range 0 –75) months, and using the log rank test and Cox regression analysis, no relevant differences in progression free survival (first quartile about 57 months and median ≥ 75 months in both groups, HR = 0.90 [95% CI: 0.47–1.72], p = 0.7500) and a negative trend in overall survival (first quartile ≥ 75 months in both groups, HR = 2.19 [95% CI: 0.75–6.41], p = 0.1419) were seen. Conclusions: Addition of G to TC did not improve efficacy in patients with stage I-IIA ovarian cancer. This was also the case for stratum II-III patients (previously reported). The addition of G to TC in patients with first diagnosis of ovarian cancer cannot be recommended. [Table: see text]

The influence of obesity on tumor recurrence in vulvar cancer patients.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17130-e17130 ◽  
Author(s):  
Rüdiger Klapdor ◽  
Peter Hillemanns ◽  
Linn Lena Woelber ◽  
Julia Kathrin Jueckstock ◽  
Felix Hilpert ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Vulvar Cancer ◽  
Cox Regression ◽  
Univariate Analysis ◽  
Disease Free Survival ◽  
Tumor Grade ◽  
Tumor Stage ◽  
Tumor Diameter ◽  
Cox Regression Analysis

e17130 Background: Obesity is associated with worse patients’ survival in several cancer entities. Vulvar cancer as well as obesity show increasing incidence over the last years. The influence of obesity on prognosis of vulvar cancer patients is not clear. However, knowledge about this may have consequences on prevention, treatment, and follow-up. Methods: This is an analysis of the large AGO-CaRE-1 study. Patients suffering from squamous cell vulvar cancer (UICC stage IB and higher), treated in 29 cancer centers between 1998 and 2008, were categorized in a database, in order to analyze treatment patterns and prognostic factors in a retrospective setting. Results: In total, 849 patients with documented height and weight were divided into two groups depending on their body mass index (BMI, < 30 vs. ≥30 kg/m²). There was no difference in the baseline variables (age, tumor diameter, depth of infiltration, tumor stage, nodal invasion, tumor grade) between both groups (p > 0.05). However, we identified differences regarding ECOG status and preexistent comorbidities (cardiovascular, dementia) towards healthier patients with BMI < 30 kg/m². Treatment variables (R0 resection, chemotherapy, radiotherapy, continuation of adjuvant therapy) did not differ (p > 0.05). Patients with BMI ≥30 kg/m² underwent radical vulvectomy more often (61.1 % vs. 51.8%, p = 0.042). During follow-up, there was a higher recurrence rate in the group having a BMI ≥30 kg/m² (43.4%, vs. 28.3%, p < 0.01) due to an increased rate of local recurrences (33.3% vs. 18.5%, p < 0.01). The rate of groin and distant recurrences was similar between both groups (p > 0.05). Noteworthy, we observed a significantly shorter disease free survival (DSF) of the obese patients in univariate analysis (HR 1.362, 95%CI 1.093-1.696, p = 0.006). Even in multivariate Cox-regression analysis including age, ECOG, tumor stage, type of surgery, nodal invasion, tumor grade, and comorbidities patients with BMI ≥30 kg/m² had a significantly shorter DFS (HR 1.811, 95%CI 1.005-3.262, p = 0.048). Conclusions: In this first large study about the association between obesity and prognosis of vulvar cancer patients, we observed that a BMI ≥30kg/m² was associated with shorter DFS, mainly attributed to a higher risk for local recurrence.

scholarly journals A Novel Prognostic Risk Score Based on Ferroptosis-related LncRNAs Predicting Ovarian Cancer Patient Survival

2021 ◽  
Author(s):  
Keyu Chen ◽  
Xiaohong Li ◽  
Caixia Qi
Keyword(s):  
Ovarian Cancer ◽  
Risk Score ◽  
Cox Regression ◽  
Characteristic Curve ◽  
Therapeutic Targets ◽  
Cancer Prognosis ◽  
Cancer Tissue ◽  
Clinical Implementation ◽  
Tumour Immunity ◽  
Cox Regression Analysis

Abstract Background: Long non-coding RNAs (lncRNAs) are thought to be associated with several processes during cancer development and have been shown to be involved in the regulation of ferroptosis. Ovarian cancer is highly malignant tumour with a poor prognosis. The identification biomarkers with prognostic value in ovarian cancer may improve patient outcomes and can help to elucidate potential future therapeutic targets.Results: We report differential expression of 187 ferroptosis-related lncRNAs in normal and ovarian cancer tissue. Using univariate and multivariable Cox regression analysis, we identified four lncRNAs that were strongly associated with prognosis. We constructed a prognostic risk score based on these four lncRNAs which was effectively able to distinguish between low- and high-risk OC patients based on survival time. Univariate and multivariable Cox regression analyses and time-related receiver operating characteristic curve analyses revealed that this risk score represented an independent prognostic factor in patients with ovarian cancer. For clinical implementation, we developed a nomogram based on the prognostic feature and patient age. Gene Ontology(GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that the four ferroptosis-related lncRNAs were related to tumour immunity.Conclusions: we identify four novel ferroptosis-related lncRNAs as predictors of ovarian cancer prognosis and potential future therapeutic targets for ovarian cancer.

scholarly journals PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma

2021 ◽  
Vol 20 ◽  
pp. 153303382110458
Author(s):  
Lin Zhou ◽  
Jing Wang ◽  
Shao-cheng Lyu ◽  
Li-chao Pan ◽  
Xian-jie Shi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Peripheral Blood ◽  
Cox Regression ◽  
Disease Free Survival ◽  
Rank Test ◽  
Cancer Tissue ◽  
Cox Regression Analysis ◽  
Poorly Differentiated ◽  
Independent Risk Factors

Background: This presented study was aimed to evaluate the diagnostic and prognostic value of PD-L1+Neutrophils (PD-L1+NEUT) and neutrophil to lymphocyte ratio (NLR) based on our previous experience of Foxp3+Treg in transplantation. Methods: the NLR cutoff value of 1.79 was used to include 136 cases from the 204 patients with hepatocellular carcinoma (HCC) confirmed by clinical pathology, which were divided into highly-moderately and poorly differentiated HCC groups. The expressions of PD-L1+NEUT and Foxp3+Treg in peripheral blood and cancer tissue were detected with flow cytometry, meanwhile, PD-L1 and Foxp3 expressed in carcinoma and para-carcinoma tissues were marked by immunohistochemistry. Survival rates, including overall survival and disease-free survival, were calculated by the Kaplan–Meier curve and evaluated with the log-rank test. Finally, Cox risk regression model was used to analyze the independent risk factors for prognostic survival. Results: The level of PD-L1+NEUT, Foxp3+Treg, and NLR in peripheral blood of patients with poorly differentiated HCC were significantly increased (all P < .001). Both PD-L1+NEUT and NLR were positively correlated with Foxp3+Treg ( r = 0.479, P = .0017; r = 0.58, P < .0001). The level of PD-L1+NEUT and Foxp3+Treg as well as PD-L1 and Foxp3 in cancer tissue and patients with poorly differentiated HCC were obviously increased (all P < .01), respectively. Cox regression analysis indicated that PD-L1+NEUT, NLR, and Foxp3+Treg were independent risk factors for the prognosis ( P = .000, .000, .006) with a RR and 95%CI of 2.704-(2.155-3.393), 3.139-(2.361-4.173), 1.409-(1.105-1.798), respectively. Conclusion: PD-L1+NEUT, NLR, and Foxp3+Treg are independent risk factors for prognosis which maybe new marker of lower survival benefits.

scholarly journals Circular RNA in Chemonaive Lymph Node Negative Colon Cancer Patients

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1903
Author(s):  
Inge van den Berg ◽  
Marcel Smid ◽  
Robert R. J. Coebergh van den Braak ◽  
Carolien H. M. van Deurzen ◽  
Vanja de Weerd ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cox Regression ◽  
Multiple Correspondence Analysis ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Stage I ◽  
Circular Rnas ◽  
Curative Surgery ◽  
Cox Regression Analysis ◽  
High Diversity

Circular RNAs (circRNAs) appear important in tumor progression of colon cancer (CC). We identified an extensive catalog of circRNAs in 181 chemonaive stage I/II colon tumors, who underwent curative surgery between 2007 and 2014. We identified circRNAs from RNAseq data, investigated common biology related to circRNA expression, and studied the association between circRNAs and relapse status, tumor stage, consensus molecular subtypes (CMS), tumor localization and microsatellite instability (MSI). We identified 2606 unique circRNAs. 277 circRNAs (derived from 260 genes) were repeatedly occurring in at least 20 patients of which 153 showed a poor or even negative (R < 0.3) correlation with the expression level of their linear gene. The circular junctions for circSATB2, circFGD6, circKMT2C and circPLEKHM3 were validated by Sanger sequencing. Multiple correspondence analysis showed that circRNAs were often co-expressed and that high diversity in circRNAs was associated with favorable disease-free survival (DFS), which was confirmed by Cox regression analysis (Hazard Ratio (HR) 0.60, 95% CI 0.38–0.97, p = 0.036). Considering individual circRNAs, absence of circMGA was significantly associated with relapse, whereas circSATB2, circNAB1, and circCEP192 were associated with both MSI and CMS. This study represents a showcase of the potential clinical utility of circRNAs for prognostic stratification in patients with stage I–II colon cancer and demonstrated that high diversity in circRNAs is associated with favorable DFS.

scholarly journals Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin

2020 ◽  
Vol 40 (2) ◽  
Author(s):  
Xiumei Wang ◽  
Yongqiang Liu ◽  
Qiong Qin ◽  
Ti Zheng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Prognostic Value ◽  
Cox Regression ◽  
Poor Response ◽  
Prognostic Indicator ◽  
Tumor Stage ◽  
Chi Square ◽  
Tissue Samples ◽  
Cox Regression Analysis

Abstract Aim: To explore the prognostic value of clusterin (CLU) in hepatocellular carcinoma (HCC) patients treated with oxaliplatin (OXA). Methods: Relative expression of plasma CLU mRNA was examined via fluorescence quantitative real-time PCR (qRT-PCR), and CLU protein level in tissue samples was detected through immunohistochemistry. Chi-square test was used to analyze the relationship between CLU mRNA expression and clinical features of HCC patients treated with OXA. Kaplan–Meier method was performed to assess overall survival for the patients, and prognostic value of CLU in HCC patients was estimated via Cox regression analysis. Results: CLU expression in plasma and tissue specimens was significantly higher among HCC patients than in non-malignant controls (P &lt; 0.001 for both). Moreover, elevated CLU mRNA was closely related to tumor stage, lymph node metastasis and response to OXA (P &lt; 0.05). HCC patients with high CLU expression showed poor response to OXA. In addition, low CLU levels predicted long overall survival time among the study subjects (20.8 vs. 36.6 months, P &lt; 0.001). CLU was an independent prognostic indicator for HCC patients treated with OXA (HR = 2.587, 95%CI = 1.749–3.828, P &lt; 0.001). Conclusion: CLU may be a novel prognostic marker for HCC patients treated with OXA.

scholarly journals Enhancing the Landscape of Colorectal Cancer Using Targeted Deep Sequencing

2020 ◽  
Author(s):  
Chul Seung Lee ◽  
In Hye Song ◽  
Ahwon Lee ◽  
Jun Kang ◽  
Yoon Suk Lee ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Poor Prognosis ◽  
Cox Regression ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Underlying Disease ◽  
Clinicopathological Characteristics ◽  
Oncologic Outcomes ◽  
Cox Regression Analysis ◽  
Targeted Next Generation Sequencing

Targeted next-generation sequencing (NGS) technology detects specific mutations that can provide treatment opportunities for colorectal cancer (CRC) patients. We included 145 CRC patients who underwent surgery. We analyzed the mutation frequencies of common actionable genes and their association with clinicopathological characteristics and oncologic outcomes using targeted NGS. Approximately 97.9% (142) of patients showed somatic mutations. Frequent mutations were observed in TP53 (70%), KRAS (49%), and APC (47%). TP53 mutations were significantly linked to higher overall stage (p=0.038) and lower disease-free survival (DFS) (p=0.039). ATM mutation was significantly associated with higher tumor stage (p=0.012) and shorter overall survival (OS) (p=0.041). Stage 3 and 4 patients with ATM mutations (p=0.023) had shorter OS, and FBXW7 mutation was significantly associated with shorter DFS (p=0.002). In multivariate Cox regression analysis, ATM mutation was an independent biomarker for poor prognosis of OS (p=0.022). TP53 and FBXW7 mutations are independent biomarkers for poor prognosis of DFS (p=0.042 and 0.030, respectively). A comprehensive analysis of the molecular markers for CRC can provide insights into the mechanisms underlying disease progression and help optimize a personalized therapy.

scholarly journals Expression of RRBP1 in epithelial ovarian cancer and its clinical significance

2019 ◽  
Vol 39 (7) ◽  
Author(s):  
Jing Ma ◽  
Sujing Ren ◽  
Jing Ding ◽  
Shuang Liu ◽  
Jiaqi Zhu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Significance ◽  
Histological Grade ◽  
Univariate Analysis ◽  
Disease Free Survival ◽  
Figo Stage ◽  
Expression Level ◽  
Interacting Protein ◽  
B Cell Leukemia

Abstract Hematopoietic pre-B cell leukemia transcription factor (PBX)-interacting protein (RRBP1) has been shown to participate in various aspects of malignancies. The clinical significance of RRBP1 and its involvement in the epithelial ovarian cancer have yet to be studied. The aim of the present study was to investigate the expression of RRBP1 in epithelial ovarian cancer (EOC) and its relationship with clinical characteristics and prognosis. We evaluated the mRNA and protein expression levels of RRBP1 by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting (n=45). Immunohistochemistry and data analysis were used to examine the relationship between the expression level of RRBP1 and the clinicopathological features and prognosis of epithelial ovarian cancer. RRBP1 was highly expressed in EOC (P<0.001). The specimens were obtained from 108 patients undergoing surgery to treat epithelial ovarian cancer. RRBP1 expression was obviously related to Federation International of Gynecologie and Obstetrigue (FIGO) stage (P<0.001), histological grade (P=0.021), histological type (P=0.004), and lymph node metastasis (P=0.012) but was not related to patient age (P=0.385) or preoperative carbohydrate antigen125 (CA125) level (P=0.238). Univariate analysis showed that the prognosis of the epithelial ovarian cancer patients was related to the age of the patients, the FIGO stage, and the expression level of RRBP1 (P<0.05). Patients with higher RRBP1 expression had significantly worse overall survival (OS) (P=0.003) and disease-free survival (DFS) (P<0.001). Multivariate survival analysis proved that RRBP1 was an independent predictor of OS (P=0.003) and DFS (P<0.001). RRBP1 plays an important role in predicting the prognosis of EOC. These results show that RRBP1 is a potential target for the treatment of epithelial ovarian cancer.

scholarly journals The expression of HOXA9 and its prognostic value in cervical cancer

2020 ◽  
Author(s):  
Keqian Zhang ◽  
Tianqi Mao ◽  
Zhicheng He ◽  
Xiaojiao Wu ◽  
Yu Peng ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Prognostic Value ◽  
Cox Regression ◽  
Figo Stage ◽  
Rank Test ◽  
Chi Square ◽  
Cox Regression Analysis ◽  
Normal Tissues ◽  
Kaplan Meier ◽  
Chi Square Test

Abstract Background The HOXA9 gene, belonging to homeobox (HOX) gene family, has been recently reported dys-expressed in several kinds of human cancers. This study aimed to investigate the expression of HOXA9 and its prognostic value in cervical cancer. Methods The HOXA9 mRNA expression was detected with a quantitative real-time polymerase chain reaction (qRT-PCR) assay, and the association of HOXA9 expression with clinical characteristic was analyzed via chi-square test. Kaplan-Meier and cox regression analyses were conducted to estimate the prognostic value of HOXA9 in cervical cancer. Results HOXA9 expression was significantly down-expressed in cervical cancer tissues compared with that in adjacent normal tissues (P < 0.01). And the expression of HOXA9 was significantly associated with TNM stage, pathological grade, FIGO stage and differentiation (All P < 0.05). In addition, Kaplan–Meier analysis indicated that the overall survival of patients with low HOXA9 expression was shorter than those with high HOXA9 expression (log rank test, P = 0.000). Cox regression analysis revealed that HOXA9 had a high prognostic value in cervical cancer. Conclusion HOXA9 is down-regulated and involved in the development of cervical cancer. Moreover, it may be an useful independent prognostic bio-marker for patients with cervical cancer.

Prognostic Impact of p53, p27, and C-MYC on Clinicopathological Features and Outcome in Early-Stage (FIGO I-II) Epithelial Ovarian Cancer

2011 ◽  
Vol 21 (2) ◽  
pp. 236-244 ◽  
Author(s):  
Ingirídur Anna Skírnisdóttir ◽  
Bengt Sorbe ◽  
Katarina Lindborg ◽  
Tomas Seidal
Keyword(s):  
Ovarian Cancer ◽  
Regression Analysis ◽  
Prognostic Factors ◽  
Cox Regression ◽  
Figo Stage ◽  
Clinicopathological Features ◽  
Positive Staining ◽  
Prognostic Impact ◽  
Cox Regression Analysis ◽  
P53 Status

Introduction:The objective of the study was to evaluate the prognostic effect of p53, p27, and C-MYC on clinicopathological features, recurrent disease, and disease-free survival (DFS) of 131 patients with ovarian cancer in International Federation of Gynecology and Obstetrics (FIGO) stages I-II.Methods:The technique of tissue microarray and immunohistochemistry was used for detection of positivity/overexpression of the biological markers p53, p27, and C-MYC.Results:In the complete series, the 5-year and overall survival rates were 68% and 71%, respectively. Positive staining for p53, p27, and C-MYC was detected in 25%, 57%, and 76% of cases, respectively. Positivity of p53, p27, concomitant p53-p27, C-MYC, and C-MYC-p27 status were associated with tumor grade. Positivity of p27 and concomitant p53-p27 were related to serous tumors. In survival analysis, DFS was related to p53, combined p53-p27, and combined p53-C-MYC status. Significant predictive factors for tumor recurrences were the FIGO stage (odds ratio [OR] = 9.8), status of node sampling (OR = 0.2), and p53 status (OR = 3.7) in a logistic regression analysis. In a multivariate Cox regression analysis, FIGO stage (hazard ratio [HR] = 4.3) and p53 status (HR = 3.0) were significant prognostic factors for DFS. In a separate Cox regression analysis, FIGO stage (HR = 2.0) and concomitant p53-p27-C-MYC status (HR = 0.3) were independent prognostic factors for DFS. It was possible to identify a subgroup, constituting 30% of the patients, who had excellent survival with tumors of concomitant p53 negativity, p27 positivity, and C-MYC positivity apart from the clinicopathological factors. Patients in this subgroup were longtime survivors with DFS of 92% at 5 and 9 years.Conclusions:The results of this study strongly suggest that patients with p53-positive tumors (alone/or combined with p27 and/or C-MYC) had significantly worse survival (DFS) compared with patients with p53-negative tumors. Patients with p53-positive tumors continued to have recurrences after the 5-year follow-up and die in disease.

Sign in / Sign up

Export Citation Format

Share Document